IA
FDMT icon

IFP Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

IFP Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04K Hold
78
– – ﹤0.01% 4483
2026
Q1 		$726 Hold
78
– – ﹤0.01% 4322
2025
Q4 		$585 Hold
78
– – ﹤0.01% 4245
2025
Q3 		$678 Buy
+78
New +$466 ﹤0.01% 4085
2025
Q2 		– Hold
0
– – – 4423
2025
Q1 		– Hold
0
– – – 4281
2024
Q4 		– Hold
0
– – – 4554

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

IFP Advisors's FDMT Position: Q2 2026 in Review

IFP Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 78 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4483.

IFP Advisors first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • IFP Advisors held 78 shares of 4D Molecular Therapeutics worth $1.04K as of Q2 2026.
  • IFP Advisors left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4483 holding.
  • IFP Advisors first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.